Highly Stable, Protein-Repellent Biomaterial Coating for Commercializing PDMS Microfluidics and Medical Devices
What it is Gel Coat Biomaterials (a University of Tokyo spin-off) offers a novel surface coating technology using a random copolymer composed of 2-methacryloyloxyethyl phosphorylcholine (MPC) and organosilanes. This coating transforms hydrophobic poly(dimethylsiloxane) (PDMS) and silicone surfaces into highly stable, hydrophilic, and protein-repellent surfaces.
Why it matters PDMS is the global standard for academic research in microfluidics due to its advantages like gas permeability. However, untreated PDMS suffers from severe hydrophobic recovery (effects disappear within hours), non-specific protein and small molecule adsorption, and poor long-term reproducibility. These inherent weaknesses have hindered the commercialization of PDMS-based devices in diagnostics, cell culture, and organ-on-a-chip (OoC). Our coating permanently eliminates these bottlenecks, ensuring lot-to-lot reproducibility and paving the way for commercial translation.
How it works The random copolymer utilizes a dual-anchoring mechanism: hydrophobic interactions (via MPTSSi units) and chemical cross-linking (via MPTMSi silane coupling) to firmly bind to the PDMS substrate. This carefully tuned polymer density and inter/intra-molecular cross-linking fundamentally suppress the polymer from restructuring into the bulk PDMS (hydrophobic recovery). The high density of MPC groups exposed on the surface provides excellent anti-biofouling properties without compromising the inherent oxygen permeability of the underlying PDMS.
Proof to date
Long-Term Stability: Maintained stable hydrophilicity and suppressed hydrophobic recovery for over 84 days (approx. 3 months) in both static and dynamic flow conditions.
Protein Non-Adsorption: Drastically reduced the non-specific adsorption of major human plasma proteins (albumin, fibrinogen, γ-globulins), thereby reducing background noise and improving diagnostic sensitivity.
3D Cell Culture: Validated in 3D cell culture applications, promoting the formation of uniform multicellular spheroids due to its robust anti-adhesion and repellent properties.
Next steps We are actively seeking joint development (JDA) and platform licensing partners. To validate our technology, we offer a fast-track 12-week Feasibility Study (PoC). We can either encapsulate and test your proprietary challenging substrates/devices (Type A) or provide our hydrogel products and protocols for your in-house testing (Type B). Our goal is to custom-tune the coating for your specific applications and fully integrate it into your commercial products.
About Gel Coat Biomaterials, inc.
Gel Coat Biomaterials, Inc. is a biotechnology startup founded in 2024 based on hydrogel technology developed by Professor Madoka Takai of the University of Tokyo. The company specializes in a proprietary biocompatible hydrogel, known as Gel Coat, which utilizes uniquely structured zwitterionic polymers to encapsulate and stabilize biomolecules such as enzymes, aptamers, nucleic acids, and cells. By surrounding these materials with a protective hydration layer, the technology enables long-term stabilization, immobilization, and thermal protection, effectively overcoming the inherent instability that often limits the application and duration of biological materials in various environments.
This technology addresses critical challenges in the bioindustry by allowing for more efficient use of biological materials. The company's solutions are targeted at applications including green chemistry to enhance sustainability, the long-term preservation of stem cells and organs, and the development of medical devices capable of generating power within the body for deep-tissue disease treatment. Supported by Series A financing from investors such as WASEDA University Ventures, the company aims to leverage its expertise in polymer chemistry and device technology to expand the utility of biomaterials across medical and industrial sectors.
delivered to your inbox.